- In February 2024, Nuvig Therapeutics, Inc. announced the administration of the first human dose of NVG-2089, a patented drug under development for treating inflammatory myopathies and severe dermatologic autoimmune diseases. The company also revealed that the FDA granted Fast Track Designation (FTD) to NVG-2089 for its development in treating bullous pemphigoid. This milestone accelerates the drug's pathway toward potential approval, highlighting its promise in addressing this rare autoimmune disorder
- In December 2023, Argenx SE announced the topline results of the ADDRESS trial, which assessed efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus vulgaris (PV) and pemphigus foliaceus (PF). The results showed no significant difference between efgartigimod SC and placebo in the proportion of PV patients achieving the primary endpoint of complete remission on a minimal steroid dose (CRmin). These findings suggest that efgartigimod SC may not provide superior efficacy compared to the placebo in achieving CRmin in PV patients
